As The Robotics Hub’s managing director in Pittsburgh, Pennsylvania, Chris Moehle invests in companies that use robotics and artificial intelligence (AI) technologies. Chris Moehle invested in Ariel Precision Medicine, which analyzes genetic data using AI to help physicians identify and treat complex chronic diseases.

Ariel Precision Medicine emphasizes the uniqueness of each patient. Two patients may experience different symptoms but the same condition. A physician runs the risk of misdiagnosing the patient by using symptoms alone to identify certain chronic diseases.

Multiple conditions may display the same symptoms. Narrowing down to the correct disease is more difficult for complex conditions. Other factors impact health, such as a patient’s genetics, family history of disease, and lifestyle. Even if a physician identifies the disease, the traditional medical approach treats the symptoms but not the underlying disease.

The ADVANCE Precision Medicine Platform uses AI to generate personalized reports per patient. They take multiple gene variants into account, including those not easily found or often ignored in widely-used genetic tests. Combined with the patient’s medical history and other unique factors, ADVANCE provides physicians with evidence-based steps to treat a patient’s condition.